Brokerages Set CytomX Therapeutics Inc (NASDAQ:CTMX) PT at $12.41

Shares of CytomX Therapeutics Inc (NASDAQ:CTMX) have received an average rating of “Buy” from the twelve ratings firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $12.56.

A number of analysts have commented on CTMX shares. Mizuho reiterated a “buy” rating and issued a $16.00 price objective on shares of CytomX Therapeutics in a research report on Friday, May 29th. Nomura Securities reduced their price objective on CytomX Therapeutics from $22.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Wedbush upgraded CytomX Therapeutics from a “neutral” rating to an “outperform” rating in a research report on Tuesday, March 24th. BidaskClub upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Finally, Jefferies Financial Group downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $16.00 to $10.00 in a research report on Monday, June 1st.

In other news, CEO Sean A. Mccarthy sold 36,000 shares of CytomX Therapeutics stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $15.00, for a total value of $540,000.00. Following the completion of the sale, the chief executive officer now directly owns 120,306 shares of the company’s stock, valued at approximately $1,804,590. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 5.80% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTMX. Point72 Asset Management L.P. acquired a new stake in shares of CytomX Therapeutics during the fourth quarter worth $5,992,000. Renaissance Technologies LLC grew its stake in shares of CytomX Therapeutics by 34.7% during the fourth quarter. Renaissance Technologies LLC now owns 2,063,271 shares of the biotechnology company’s stock worth $17,146,000 after purchasing an additional 530,971 shares during the period. Panagora Asset Management Inc. acquired a new stake in shares of CytomX Therapeutics during the fourth quarter worth $4,010,000. EcoR1 Capital LLC acquired a new stake in shares of CytomX Therapeutics during the fourth quarter worth $3,407,000. Finally, Marshall Wace LLP grew its stake in shares of CytomX Therapeutics by 4,902.2% during the fourth quarter. Marshall Wace LLP now owns 401,426 shares of the biotechnology company’s stock worth $3,336,000 after purchasing an additional 393,401 shares during the period. 78.59% of the stock is owned by institutional investors.

Shares of NASDAQ CTMX traded down $0.36 during mid-day trading on Friday, reaching $8.20. 735,047 shares of the company traded hands, compared to its average volume of 723,214. The stock has a market cap of $393.10 million, a PE ratio of -4.85 and a beta of 0.70. The company’s fifty day moving average is $9.34 and its two-hundred day moving average is $8.06. The company has a debt-to-equity ratio of 0.35, a quick ratio of 3.77 and a current ratio of 3.77. CytomX Therapeutics has a fifty-two week low of $3.60 and a fifty-two week high of $15.44.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Thursday, May 7th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.60. The firm had revenue of $49.59 million for the quarter, compared to analyst estimates of $26.93 million. CytomX Therapeutics had a negative return on equity of 99.72% and a negative net margin of 97.83%. Research analysts forecast that CytomX Therapeutics will post -0.48 earnings per share for the current year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Featured Article: Is a Roth IRA right for you?

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.